Patients received cabozantinib 100 mg daily during a 12-week lead-in. The melanoma cohort included 23 patients with metastatic uveal melanoma.The majority (9/10) of patient samples analysed for GNAQ/GNA11 mutation status harboured either a GNAQ (n=5) or GNA11 mutation (n=4)...In the uveal melanoma cohort, 61% of patients (14/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS rate at 6 months; Figure 3B), and median OS was 12.6 months (Figure 3C).